يعرض 1 - 12 نتائج من 12 نتيجة بحث عن '"Coagulation factor concentrate"', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
    Academic Journal
  4. 4
    Academic Journal

    وصف الملف: application/pdf

    Relation: Roberts, Sammie J.; Pokrandt, Paul; Jewell, Elizabeth; Engoren, Milo; Berg, Mary P.; Maile, Michael D. (2021). "Association of four‐factor prothrombin complex concentrate with subsequent plasma transfusion: A retrospective cohort study." Transfusion Medicine 31(1): 69-75.; https://hdl.handle.net/2027.42/166423; Transfusion Medicine; Kushimoto S, Fukuoka T, Kimura A, et al. Efficacy and safety of a 4‐factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open‐label, single‐arm phase 3b study. Int J Hematol. 2017; 106 ( 6 ): 777 ‐ 786.; Brekelmans MPA, Ginkel KV, Daams JG, Hutten BA, Middeldorp S, Coppens M. Benefits and harms of 4‐factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta‐analysis. J Thromb Thrombolysis. 2017; 44 ( 1 ): 118 ‐ 129.; Cappabianca G, Mariscalco G, Biancari F, et al. Safety and efficacy of prothrombin complex concentrate as first‐line treatment in bleeding after cardiac surgery. Crit Care. 2016; 20: 5.; CSL Behring. Kcentra: Full Prescribing Information. Bradley, IL. 2018.; Demeyere R, Gillardin S, Amount J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010; 99: 251 ‐ 260.; Ellingson KD, Sapiano MRP, Haass KA, et al. Continued decline in blood collection and transfusion in the United States—2015. Transfusion. 2017; 57 ( Suppl 2 ): 1588 ‐ 1598.; Enter DH, Zaki AL, Marsh M, et al. Prothrombin complex concentrate reduces blood product utilization in heart transplantation. Pharmacotherapy. 2017; 37 ( 10 ): 1215 ‐ 1220.; Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four‐factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open‐label, non‐inferiority, randomized trial. Lancet. 2015; 385 ( 9982 ): 2077 ‐ 2087.; Grandhi R, Newman WC, Zhang X, et al. Administration of 4‐factor Prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg. 2015; 84 ( 6 ): 1956 ‐ 1961.; Huang WT, Cang WC, Derry KL, Lane JR, von Drygalski A. Four‐factor Prothrombin complex concentrate for coagulopathy reversal in patients with liver disease. Clin Appl Thromb Hemost. 2017; 23 ( 8 ): 1028 ‐ 1035.; Johansen M, Wikkelse A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non‐bleeding patients. Cochrane Database Syst Rev. 2015; 7 ( 7 ): CD10555.; Jones CA, Ducis K, Petrozzino J, et al. Prevention of treatment‐related fluid overload reduces estimated effective cost of prothrombin complex concentrate in patients requiring rapid vitamin K antagonist reversal. Expert Rev Pharmacoecon Outcomes Res. 2016; 16 ( 1 ): 135 ‐ 139.; Kamath P, Kim W, Advanced Liver Disease Study Group. The model for end‐stage liver disease (MELD). Hepatology. 2007; 45 ( 3 ): 797 ‐ 805.; Kcentra: Product Information. In Micromedex RED BOOK. Greenwood Village, CO: Truven Health Analytics; 2018.; Khorsand N, Giepmans L, Meijer K, van Hest RM, Veeger NJ. A low fixed dose of prothrombin complex concentrate is cost effective in emergency reversal of vitamin K antagonists. Haematologica. 2013; 98 ( 6 ): e65 ‐ e67.; Lin DM, Murphy LS, Tran MH. Use of prothrombin complex concentrate and fibrinogen concentrates in the perioperative setting: a systematic review. Transfus Med Rev. 2013; 27 ( 2 ): 91 ‐ 104.; R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2018 https://www.R-project.org/. Accessed 3 January 2019.; Rivosecchi RM, Durkin J, Okonkwo DO, Molyneaux BJ. Safety and efficacy of warfarin reversal with four‐factor Prothrombin complex concentrate for subtherapeutic INR in Intracerebral hemorrhage. Neurocrit Care. 2016; 25 ( 3 ): 359 ‐ 364.; Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4‐factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma‐controlled, phase IIIb study. Circulation. 2013; 128 ( 11 ): 1234 ‐ 1243.; Shih AW, Kolesar E, Ning S, Manning N, Arnold DM, Crowther MA. Evaluation of the appropriateness of frozen plasma usage after introduction of prothrombin complex concentrates: a retrospective study. Vox Sang. 2015; 108 ( 3 ): 274 ‐ 280.; Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomized trial. Lancet Neurol. 2016; 15 ( 6 ): 566 ‐ 573.; Triulzi D, Gottschall J, Murphy E, et al. A multicenter study of plasma use in the United States. Transfusion. 2015; 55 ( 6 ): 1313 ‐ 1319.; Arshad F, Ickx B, van Beem RT, et al. Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON‐trial. BMC Surg. 2013; 13: 22.; Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin‐related intracranial hemorrhage. Neurosurgery. 1999; 45: 1113 ‐ 1119.

  5. 5
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
  9. 9
  10. 10
    Academic Journal
  11. 11
    Electronic Resource
  12. 12
    Electronic Resource